在患有心房的患者组合手术的战略优化:组合随机临床试验
Xianfeng Du1,2, Huimin Chu1,2, Bing Yang3
1Arrhythmia Center, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, China.
JAMA network open
|November 15, 2024
概括
对于心房动 (AF) 患者的左心房附属物阻塞 (LAAO) 和导管切除 (CA) 的结合性闭塞第一策略,与切除第一策略相比,显示出更高的无事件存活率和无心房动脉节律失常 (ATA) 的自由. 这表明,封闭率先是首选的方法.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 电子生理学 电子生理学
背景情况:
- 在心房动 (AF) 患者中,将左心房尾封闭 (LAAO) 与导管切除 (CA) 结合在一起的最佳顺序尚不清楚.
- 这项研究解决了临床问题,即废除先或封闭先的策略是否会产生更好的长期结果.
研究的目的:
- 为了比较非膜性AF患者进行LAAO和CA组合治疗的ABlation-first与Occlusion-first策略的长期临床结果.
- 评估两种程序序列的安全性和有效性.
主要方法:
- 一个前性的多中心随机临床试验 (组合试验) 涉及202名非关节性AF患者.
- 患者被随机分配到一个移除第一组或封闭第一组,接受LAAO与封闭装置和CA与接触力传感导管.
- 主要终点是血栓栓塞事件,设备相关的血栓,出血和心血管再住院或死亡的复合. 二级终点包括没有AF/心房动脉节律失常 (ATA).
主要成果:
- 闭塞第一组的无事件生存率 (83.5%与71.1%) 和长期无AF (77.3%与63.5%) 和ATA (70.1%与55.7%) 的显着较高,与去除第一组相比.
- 摘除第一组的慢性周周器件泄漏和与器件相关的血栓的发病率更高.
- 两组之间没有观察到周围手术并发症的显著差异.
结论:
- 在接受LAAO和CA组合治疗的患者中,闭塞第一方法在无事件生存和长期无心脏不律症方面优越.
- 研究结果支持建议在涉及插件式设备植入的联合手术中采用闭塞优先策略.
相关概念视频
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K


